WO2008133225A1 - 急性肝炎の治療又は劇症肝炎の予防・治療剤 - Google Patents

急性肝炎の治療又は劇症肝炎の予防・治療剤 Download PDF

Info

Publication number
WO2008133225A1
WO2008133225A1 PCT/JP2008/057656 JP2008057656W WO2008133225A1 WO 2008133225 A1 WO2008133225 A1 WO 2008133225A1 JP 2008057656 W JP2008057656 W JP 2008057656W WO 2008133225 A1 WO2008133225 A1 WO 2008133225A1
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
remedy
fulminant
preventive
fulminant hepatitis
Prior art date
Application number
PCT/JP2008/057656
Other languages
English (en)
French (fr)
Inventor
Tetsuya Sasaki
Naoko Hara
Makoto Ishikawa
Original Assignee
Nihon Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Pharmaceutical Co., Ltd. filed Critical Nihon Pharmaceutical Co., Ltd.
Priority to JP2009511866A priority Critical patent/JPWO2008133225A1/ja
Priority to US12/450,835 priority patent/US20110201548A1/en
Priority to EP08740701A priority patent/EP2140874A4/en
Publication of WO2008133225A1 publication Critical patent/WO2008133225A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

【課題】急性肝炎が劇症肝炎に進行すると、肝細胞の破壊が急激かつ大量に発生する結果、予後は極めて不良となる。従って急性肝炎から劇症化への進行を早くに予知し、速やかに適切な処置を開始することが肝要である。しかし近年検査方法や診断技術の向上から肝炎劇症化の予知が可能になってきたにもかかわらず、劇症肝炎の適切な予防・治療剤がなかった。本発明の課題は、副作用の少ない急性肝炎の治療又は劇症肝炎の予防・治療剤を提供することにある。 【解決手段】アポリポタンパク質Ａ－IIを含有する医薬組成物が前記課題を解決した。
PCT/JP2008/057656 2007-04-23 2008-04-21 急性肝炎の治療又は劇症肝炎の予防・治療剤 WO2008133225A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009511866A JPWO2008133225A1 (ja) 2007-04-23 2008-04-21 急性肝炎の治療又は劇症肝炎の予防・治療剤
US12/450,835 US20110201548A1 (en) 2007-04-23 2008-04-21 Therapeutic agent for acute hepatitis or prophylactic/therapeutic agent for fulminant hepatitis
EP08740701A EP2140874A4 (en) 2007-04-23 2008-04-21 FOR THE TREATMENT OF ACUTE HEPATITIS OR FOR THE PREVENTION / TREATMENT OF FULMINATE HEPATITIS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007112690 2007-04-23
JP2007-112690 2007-04-23

Publications (1)

Publication Number Publication Date
WO2008133225A1 true WO2008133225A1 (ja) 2008-11-06

Family

ID=39925676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057656 WO2008133225A1 (ja) 2007-04-23 2008-04-21 急性肝炎の治療又は劇症肝炎の予防・治療剤

Country Status (6)

Country Link
US (1) US20110201548A1 (ja)
EP (1) EP2140874A4 (ja)
JP (1) JPWO2008133225A1 (ja)
CN (1) CN101668537A (ja)
TW (1) TW200906433A (ja)
WO (1) WO2008133225A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023502496A (ja) 2019-11-20 2023-01-24 アルカヘスト，インコーポレイテッド 肝臓再生に使用するための血漿画分
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
JP2024521695A (ja) * 2021-05-19 2024-06-04 アルカヘスト，インコーポレイテッド 肝臓再生に使用するための血漿画分

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63237789A (ja) 1987-03-24 1988-10-04 Otsuka Pharmaceut Factory Inc プロアポリポタンパク質遺伝子、対応プラスミド組換体及び対応形質転換体
JPH05221858A (ja) 1991-02-28 1993-08-31 Ajinomoto Co Inc 肝炎治療薬
JPH07304689A (ja) 1994-05-10 1995-11-21 Sumitomo Pharmaceut Co Ltd 劇症肝炎ならびに急性肝不全治療剤
JPH09143094A (ja) 1995-11-16 1997-06-03 Fujisawa Pharmaceut Co Ltd 劇症肝炎の予防治療剤
JP3734593B2 (ja) 1997-04-25 2006-01-11 ヒゲタ醤油株式会社 新規発現プラスミドベクター及び該発現プラスミドベクターを保有するバチルス属細菌を用いた異種遺伝子産物の製造法
JP2008017777A (ja) 2006-07-13 2008-01-31 Tottori Univ 肝炎の診断キット及び診断マーカー

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2428114C (en) * 2000-11-10 2013-07-23 Proteopharma Aps Apolipoprotein analogues
WO2005086578A2 (en) * 2004-03-08 2005-09-22 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-inflammatory peptides and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63237789A (ja) 1987-03-24 1988-10-04 Otsuka Pharmaceut Factory Inc プロアポリポタンパク質遺伝子、対応プラスミド組換体及び対応形質転換体
JPH05221858A (ja) 1991-02-28 1993-08-31 Ajinomoto Co Inc 肝炎治療薬
JPH07304689A (ja) 1994-05-10 1995-11-21 Sumitomo Pharmaceut Co Ltd 劇症肝炎ならびに急性肝不全治療剤
JPH09143094A (ja) 1995-11-16 1997-06-03 Fujisawa Pharmaceut Co Ltd 劇症肝炎の予防治療剤
JP3734593B2 (ja) 1997-04-25 2006-01-11 ヒゲタ醤油株式会社 新規発現プラスミドベクター及び該発現プラスミドベクターを保有するバチルス属細菌を用いた異種遺伝子産物の製造法
JP2008017777A (ja) 2006-07-13 2008-01-31 Tottori Univ 肝炎の診断キット及び診断マーカー

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL BIOCHEMISTRY, vol. 178, 1989, pages 301 - 305
CLINICAL PATHOLOGY, vol. XXIX, no. 2, 1981, pages 135 - 138
FUKUSHIMA M.: "Merck Manual", vol. 17TH ED., 1999, NIKKEI BUSINESS PUBLICATIONS, INC., pages: 379 - 386, XP008120784 *
HIDEKI TOHDA, KOSO KOGAKU NEWS, vol. 57, April 2007 (2007-04-01)
KALOPISSIS A.D. ET AL.: "Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance", CURR. OPIN. LIPIDOL., vol. 14, no. 2, 2003, pages 165 - 172, XP008120079 *
OKAZAKI ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 6485 - 6489
See also references of EP2140874A4
TAKEZAKI E. ET AL.: "Kan Shogai no Shihyo to Shiteno Apolipo Tanpaku A-I, A-II no Rinshoteki Kento", IRYO, vol. 43, no. 6, 1989, pages 625 - 630, XP008120113 *
THE LIPID, vol. 2, no. 3, 1991, pages 243 - 249

Also Published As

Publication number Publication date
EP2140874A1 (en) 2010-01-06
EP2140874A4 (en) 2010-10-20
US20110201548A1 (en) 2011-08-18
TW200906433A (en) 2009-02-16
CN101668537A (zh) 2010-03-10
JPWO2008133225A1 (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
WO2009032321A3 (en) A method for treating diabetes
HRP20181232T1 (hr) Komplet za regeneraciju masnog tkiva i postupak njegove upotrebe
HK1220612A1 (zh) 治療炎症相關疾病的方法
EP2004040A4 (en) METHOD AND APPARATUS FOR NON-INVASIVE MEASUREMENT OF TISSUE FUNCTION AND TISSUE METABOLISM THROUGH THE DETERMINATION OF STABLE FLUORESCENCE ANISOTROPY
BRPI0907663A8 (pt) composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições
EP2179037A4 (en) DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES
SG169327A1 (en) Compositions and methods of use for antibodies of dickkopf-1 and/or -4
WO2007130636A3 (en) Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
EP2262366A4 (en) COMPOUNDS AND METHODS FOR TREATING STROGEN RECEPTOR-RELATED DISEASES
EP2040849A4 (en) CENTRIFUGE AND CENTRIFUGATION PROCESS
EP2037272A4 (en) KIT AND METHOD FOR DETECTING OR BZW. FOR QUANTIFYING AN ANALYTE
EP1834166A4 (en) APPARATUS FOR EXECUTING OPERATING PROCESSES OF OBJECT-HOLDER BLADES WITH TISSUE SPECIMENS
PT2290370E (pt) Método de determinação da causa do prolongamento do tempo de coagulação do sangue
DK2288364T3 (da) Fremgangsmåder til behandling eller forebyggelse af diabetes mellitus og andre metaboliske ubalancer
EP1774029A4 (en) METHOD FOR DETECTING THE RISKS OF NON-INSULIN-DEPENDENT DIABETES AND FOR TREATING THIS TYPE OF DIABETES
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
BRPI0916639A2 (pt) método para aumentar a quantidade de precipitação em uma região alvo, aparelho para modificação do tempo, e, uso do aparelho.
WO2010120143A3 (ko) 간암 예후 마커
WO2007085497A3 (en) Markers for the prediction of outcome of anthracycline treatment
BRPI0817448A2 (pt) Composto, composição farmacêutica, método para prevenção ou tratamento de uma condição patológica ou sintoma em um mamífero, uso de um composto, e, kit
WO2008133225A1 (ja) 急性肝炎の治療又は劇症肝炎の予防・治療剤
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
PL2183422T3 (pl) Sposób obróbki wsadu oraz nadająca się do niego, sterowana programowo pralka
DK2012814T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme
EP2341945A4 (en) METHOD AND THERAPIES FOR THE TREATMENT OF INFLAMMATORY DISEASES WITH EXPOSED COLLAGEN

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880013381.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740701

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009511866

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12450835

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008740701

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE